Isoray - Innovative Brachytherapy

Isoray Nasdaq Market Site Interview with Tom LaVoy, Chairman and CEO, November 26, 2017

Dec 7, 2017

Isoray CEO Tom Lavoy recently spoke with LilaMax Media CEO Jane King in an interview with Nasdaq Market Site. Topics range from the benefits of Cesium-131 brachytherapy for brain cancer, gynecologic cancer, prostate cancer and the company’s clinical strides made in the past 10 years.

Isoray passionately designs and develops innovative and personalized brachytherapy products that effectively treat many forms of cancer. We believe in pioneering solutions for life beyond your cancer.

Make sure to watch the full Isoray Nasdaq Market site interview if you are interested in learning more about the latest advancements in Cesium-131 brachytherapy visit our blog, complete with inspiring patient stories, clinician spotlights and the latest scientific data on Cesium-131 brachytherapy and its ability to improve outcomes for certain types of cancer patients.

One cancer survivor now a pioneer in brachytherapy and radiation oncology

“Quality of life has really come to the forefront, which it should. Today, we are able to select patients for appropriate therapy always keeping in mind quality of life [post treatment] is paramount. If you don’t maintain it, some men can go into depression and snowball into multi-factorial healthcare conditions.” – Dr. Brian Moran, Chicago Prostate Cancer Center.

Interested investors should contact: